Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years

I

Institute of Medical Biology, Chinese Academy of Medical Sciences

Status and phase

Completed
Phase 2
Phase 1

Conditions

COVID-19

Treatments

Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Biological: Placebo on a 0- and 28-day schedule

Study type

Interventional

Funder types

Other

Identifiers

NCT04470609
20200402

Details and patient eligibility

About

This study is a randomized, double-blinded, and placebo-controlled phase Ib/IIb clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged ⩾60 Years.

Full description

This phase Ib/IIb trial is designed to evaluate the safety and immunogenicity of different doses of the Inactivated SARS-CoV-2 Vaccine based upon the randomized, double-blind and placebo-controlled principle. A total of 471 subjects aged ⩾60 years will be enrolled in the study, of which 96 and 375 will be enrolled for phase Ib and phase Ⅱb,respectively. The enrolled subjects in phase Ib receive two doses of low-, medium-, or high-dose of experimental vaccines or placebo at an interval of 28 days, while the enrolled subjects in Phase Ⅱb receive two doses of medium, high-dose experimental vaccines or placebo at an interval of 28 days.

Enrollment

471 patients

Sex

All

Ages

60+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Phase Ib:

  • Healthy people aged ⩾60 years (including boundary values), both men and women.
  • Proven legal identity.
  • Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
  • Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
  • Axillary temperature ≤37.0 ℃.

Phase IIb:

  • Healthy people aged ⩾60 years (including boundary values), both men and women.
  • Proven legal identity.
  • Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
  • Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
  • Axillary temperature ≤37.0 ℃.

Exclusion criteria

Phase Ib:

  • Contraindications for vaccination.
  • History of allergy to vaccines or drugs.
  • Immunization with any vaccine within 1 month.
  • Diseases that cannot be controlled by drugs, such as hypertension, diabetes, asthma, etc.
  • Those who developed acute disease within 2 weeks, or had symptoms of fever or upper respiratory tract infection within 7 days.
  • Those who have a hereditary bleeding tendency or coagulation dysfunction, or a history of thrombosis or bleeding disorders.
  • Those who cannot tolerate venipuncture, or have a history of halo needles or halo blood.
  • For any reason, the spleen was removed partially or completely.
  • Those who have undergone surgery within 3 months before signing the informed consent, or those who plan to perform surgery during the trial or within 3 months after the end of the trial (including cosmetic surgery, dental and oral surgery).
  • Those who donated or lost blood (≥200 mL) in the past 3 months, who received blood transfusion or use of blood products, or who planned blood donation during the trial.
  • Receipt of other investigational or unregistered products (drugs, vaccines, biological product or devices) in the past 3 months, or plan to use other investigational or unregistered products during the study.
  • Receipt of immunosuppressive therapy within 6 months before signing the informed consent form, such as long-term systemic glucocorticoid therapy (with systemic glucocorticoid therapy for more than 2 weeks within 6 months, such as prednisone or similar drugs) ), but local administration (such as ointment, eye drops, inhalation, or nasal spray) is allowed. The local administration should not exceed the dosage recommended in the instructions or have any signs of systemic exposure.
  • Those who have took soft drugs (such as marijuana) within 3 months before signing the informed consent form or took hard drugs (such as: cocaine, phencyclidine, etc.) within 1 year before the trial.
  • Those who smoked more than 5 cigarettes per day within 3 months before signing the informed consent form.
  • The weekly drinking volume is greater than 14 units within 3 months before signing the informed consent form (1 unit alcohol approximately equal to 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine).
  • The comprehensive physical examination does not meet the health standards, mainly including: (1) Those with abnormal vital signs with clinical significance. (2) BMI<18 kg/m^2 or> 30 kg/m^2. (3) Abnormal laboratory examination with clinical significance. (4) Those who tested positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis B e antigen, hepatitis C virus antibody, or Treponema pallidum antibody (tp-trust).
  • Women who have a positive pregnancy test, or men who have a birth plan or plan to donate sperm from the screening to 12 months after the second vaccination.
  • Positive in drug abuse screening during the screening period (Morphine, Methamphetamine, Ketamine, MDMA and Tetrahydrocannabinolic acid).
  • Positive in alcohol breath test during the screening period.
  • Positive in SARS-CoV-2 nucleic acid screening or antibodies (IgG or IgM) screening.
  • History of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) or other coronavirus infection (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1).
  • History of contact with confirmed or suspected cases infected with SARS-CoV-2 within 1 month.
  • Any other situations judged by investigators as not suitable for participating in this study.

Phase IIb:

  • Contraindications for vaccination.
  • History of allergy to vaccines or drugs.
  • Immunization with any vaccine within 1 month.
  • Diseases that cannot be controlled by drugs, such as hypertension, diabetes, asthma, etc.
  • Those who developed acute disease within 2 weeks, or had symptoms of fever or upper respiratory tract infection within 7 days.
  • Those who have a hereditary bleeding tendency or coagulation dysfunction, or a history of thrombosis or bleeding disorders.
  • For any reason, the spleen was removed partially or completely.
  • Those who have undergone surgery within 3 months before signing the informed consent, or those who plan to perform surgery during the trial or within 3 months after the end of the trial (including cosmetic surgery, dental and oral surgery).
  • Those who donated or lost blood (≥200 mL) in the past 3 months, who received blood transfusion or use of blood products, or who planned blood donation during the trial.
  • Receipt of other investigational or unregistered products (drugs, vaccines, biological product or devices) in the past 3 months, or plan to use other investigational or unregistered products during the study.
  • Receipt of immunosuppressive therapy within 6 months before signing the informed consent form, such as long-term systemic glucocorticoid therapy (with systemic glucocorticoid therapy for more than 2 weeks within 6 months, such as prednisone or similar drugs) ), but local administration (such as ointment, eye drops, inhalation, or nasal spray) is allowed. The local administration should not exceed the dosage recommended in the instructions or have any signs of systemic exposure.
  • Women who have a positive pregnancy test, or men who have a birth plan or plan to donate sperm from the screening to 12 months after the second vaccination.
  • History of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) or other coronavirus infection (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1).
  • History of contact with confirmed or suspected cases infected with SARS-CoV-2 within 1 month.
  • The comprehensive physical examination does not meet the health standards, mainly including: (1) Those with abnormal vital signs (Pulse <55 beats per minute or> 100 beats per minute at rest, Systolic blood pressure ≥140mmHg or Diastolic blood pressure ≥90mmHg, breathing> 20 beats per minute or <12 beats per minute). (2) Those who tested positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis B e antigen, hepatitis C virus antibody, or Treponema pallidum antibody (tp-trust).
  • Positive in SARS-CoV-2 nucleic acid screening or antibodies (IgG or IgM) screening.
  • Any other situations judged by investigators as not suitable for participating in this study.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

471 participants in 4 patient groups, including a placebo group

Low dosage vaccine on a 0- and 28-day schedule
Experimental group
Description:
Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
Treatment:
Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Medium dosage vaccine on a 0- and 28-day schedule
Experimental group
Description:
Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
Treatment:
Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
High dosage vaccine on a 0- and 28-day schedule
Experimental group
Description:
Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28
Treatment:
Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Placebo on a 0- and 28-day schedule
Placebo Comparator group
Description:
Two doses of placebo at the vaccination schedule of day 0, 28
Treatment:
Biological: Placebo on a 0- and 28-day schedule

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems